Clinical experience with Filgrastim in AIDS.
Data have shown that neutropenia is a risk factor for severe bacterial infections. Two trials were done in HIV-infected patients to study the effect of Filgrastim on neutropenia and the incidence of severe bacterial infections. The incidence of Mycobacterium avium complex (MAC) infection in this setting was also evaluated. This paper reviews the results of these two studies, which suggest that Filgrastim is safe and effective in preventing severe neutropenia in patients with advanced HIV infection.
Kuritzkes
D R
DR
University of Colorado Health Sciences Center, Denver 80262, USA.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy*; D001424:Bacterial Infections / Q000209:etiology / Q000517:prevention & control; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D015270:Mycobacterium avium-intracellulare Infection / Q000209:etiology / Q000517:prevention & control; D009503:Neutropenia / Q000209:etiology / Q000517:prevention & control*; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim